Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Drugmaker Endo settles opioid claims by N.Y., counties for $50M

Reprints
Endo

(Reuters) – Drugmaker Endo International PLC on Thursday said it has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids.

Endo said the settlement includes no admission of wrongdoing by Endo or its subsidiaries.

The settlement severs Endo from an ongoing trial in lawsuits by New York Attorney General Letitia James and Suffolk and Nassau counties. Claims against AbbVie Inc. and Teva Pharmaceutical Industries remain pending.

The deal came after the nation’s three largest drug distributors — McKesson Corp., AmerisourceBergen and Cardinal Health — as well as Johnson & Johnson on Saturday said they would move forward with a proposed national $26 billion settlement resolving opioid cases against them.

Dublin-based Endo is not part of that deal.

“While litigation of the remaining opioid claims is ongoing, Endo is focused on its primary goal of achieving a global settlement,” the company said. “Endo is also currently exploring other strategic alternatives and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement.”

Hunter Shkolnik, a lawyer for Nassau County, said he was “happy our clients can get closure and it has kept Endo out of bankruptcy, that would have hurt everyone.”

In July, Endo agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic.

New York attorney general’s spokesperson didn’t immediately respond to a Reuters request for comment.

Endo had removed its long-lasting opioid painkiller Opana ER from the market in July 2017.

 

 

Read Next

  • Drugmaker Endo to pay $10M to settle opioid case

    (Reuters) — Endo International PLC on Tuesday said it had agreed to pay $10 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.